Asleh, K., Lluch, A., Goytain, A., Barrios, C., Wang, X., Torrecillas, L., . . . Martin, M. (2023). Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Chicago Style CitationAsleh, K., et al. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit From Extended Adjuvant Capecitabine. 2023.
MLA CitationAsleh, K., et al. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit From Extended Adjuvant Capecitabine. 2023.
Warning: These citations may not always be 100% accurate.